Positive CLL Data For AstraZeneca's BTK Inhibitor Prompts Early ASCEND Trial End

 
• By Sten Stovall
  
Leukemia
Calquence is being developed for the treatment of multiple B-cell blood cancers including CLL. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D